EssexBio

Essex-Bio Group

简繁 EN

ANNOUNCEMENTS & SHAREHOLDER INFORMATION

Normative Disclosure, Honest Communication

Date

Title

File

Times

2023-02-24

NOTICE OF BOARD MEETING

952

2023-02-22

UPDATE ON DISCLOSEABLE TRANSACTION AMENDMENT AGREEMENT TO THE CO-DEVELOPMENT LICENSE AGREEMENT WITH SHANGHAI HENLIUS BIOTECH, INC. FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION

939

2023-02-10

VOLUNTARY ANNOUNCEMENT FIRST PATIENT FIRST DOSE COMPLETED IN THE UNITED STATES IN AN INTERNATIONAL MULTI-CENTRE PHASE 3 CLINICAL STUDY IN RELATION TO THE CO-DEVELOPMENT OF THE LICENSED PRODUCT WITH HENLIUS FOR THE TREATMENT OF EXUDATIVE (WET) AGE-RELATED MACULAR DEGENERATION

998

2023-02-02

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JANUARY 2023

970

2023-01-10

1056

2023-01-04

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 DECEMBER 2022

990

2022-12-29

NEXT DAY DISCLOSURE RETURN

1049

2022-12-21

NEXT DAY DISCLOSURE RETURN

1024

2022-12-02

NEXT DAY DISCLOSURE RETURN

1068

2022-12-02

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 NOVEMBER 2022

979

2022-12-01

NEXT DAY DISCLOSURE RETURN

999

2022-11-30

NEXT DAY DISCLOSURE RETURN

1026

2022-11-28

NEXT DAY DISCLOSURE RETURN

996

2022-11-25

NEXT DAY DISCLOSURE RETURN

985

2022-11-24

NEXT DAY DISCLOSURE RETURN

1045

2022-11-23

NEXT DAY DISCLOSURE RETURN

950

2022-11-22

NEXT DAY DISCLOSURE RETURN

967

2022-11-21

NEXT DAY DISCLOSURE RETURN

922

2022-11-18

NEXT DAY DISCLOSURE RETURN

964

2022-11-17

NEXT DAY DISCLOSURE RETURN

914

This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.

ACCEPT